论证精确剂量:可视化严重病情的成年人中塞费皮姆暴露的变化
Jack Chang1,2,3, Jiajun Liu4,5, Mohammad H Alshaer6,7
1Department of Pharmacy Practice, Midwestern University College of Pharmacy, 555 31st St., Downers Grove, IL 60515, USA.
The Journal of antimicrobial chemotherapy
|July 14, 2023
概括
现实世界cefepime (抗生素) 暴露在重症患者中存在很大差异. 仅基于肌素清除的标准剂量调整是不够的,冒着低于最佳治疗的风险.
科学领域:
- 药理动力学和药理动力学
- 关键护理医学 关键护理医学
- 抗生素药物监测 抗生素药物监测
背景情况:
- 塞菲皮姆是治疗重症病房 (ICU) 中严重感染的关键抗生素.
- 了解cefepime暴露变异性对于优化重症监护机构患者的治疗结果至关重要.
研究的目的:
- 用人群药动力学建模,量化重病患者Cefepime暴露的变异性.
- 评估肌素清除率对预测塞费皮姆暴露的充分性,并指导剂量策略.
主要方法:
- 使用75名成年ICU患者的数据,采用了人口药理动力学建模 (两部分模型).
- 对1000名患者进行了模拟,以估计塞费皮姆清除率和暴露变异性.
- 可视化了可变性,并分析了10名代表性模拟患者,以说明暴露差异.
主要成果:
- 观察到cefepime清除的显著变化 (CV: 45%-95%),当对肌素清除进行校正时,人口模型偏差略有改善.
- 模拟患者具有相似的肌素清除,在最大度Cefepime的8倍以上的差异.
- 清除概况显示,尽管估计的功能相似,但患者间存在很大差异.
结论:
- 单独的肌素清除不足以预测ICU患者的塞费皮姆暴露.
- 存在显著的cefepime暴露变异性,即使估计的功能类似.
- 目前仅基于肌素清除量的剂量调整可能会导致安全性和有效性问题.
更多相关视频
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
7.0K
07:16Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
Published on: September 20, 2024
1.1K
相关概念视频
Drug Concentration Versus Time Correlation
895
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
895
Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters
131
The noncompartmental approach is a widely used method in pharmacokinetics to assess drugs' behaviors in the body. It considers several factors, including clearance, bioavailability, and total volume of distribution.
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
131
